Dacarbazine
- Generic Name
- Dacarbazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
- Associated Therapies
- -
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Genta Incorporated
- Registration Number
- NCT00016263
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Genta Incorporated, Berkeley Heights, New Jersey, United States
Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 850
- Registration Number
- NCT00041210
- Locations
- 🇬🇧
Pinderfields General Hospital, Wakefield, Scotland, United Kingdom
🇬🇧Aintree University Hospital, Liverpool, England, United Kingdom
🇬🇧City Hospital - Birmingham, West Bromwich, England, United Kingdom
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 46
- Registration Number
- NCT00004141
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 260
- Registration Number
- NCT00025064
- Locations
- 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
- Conditions
- Locations
- 🇩🇪
Carl - Thiem - Klinkum Cottbus, Cottbus, Germany
🇩🇪Klinikum Lippe - Detmold, Detmold, Germany
🇩🇪Praxis am Evangelischen Krankenhaus Bethanien, Iserlohn, Germany
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 552
- Registration Number
- NCT00049595
- Locations
- 🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇧🇪Clinique Universitaire De Mont-Godinne, Yvoir, Belgium
🇦🇺Canberra Hospital, Garran, Australian Capital Territory, Australia
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT00002882
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00038558
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-27
- Target Recruit Count
- 27
- Registration Number
- NCT00000626
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
🇺🇸SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
🇺🇸The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
Thalidomide and Dacarbazine for Metastatic Melanoma
- Conditions
- First Posted Date
- 2000-09-11
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00006200
- Locations
- 🇺🇸
Kaplan Comprehensive Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.